155 related articles for article (PubMed ID: 31086057)
1. Niemann-Pick Type A Disease: Behavior of Neutral Sphingomyelinase and Vitamin D Receptor.
Conte C; Arcuri C; Cataldi S; Mecca C; Codini M; Ceccarini MR; Patria FF; Beccari T; Albi E
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31086057
[TBL] [Abstract][Full Text] [Related]
2. Sphingomyelin-induced inhibition of the plasma membrane calcium ATPase causes neurodegeneration in type A Niemann-Pick disease.
Pérez-Cañamás A; Benvegnù S; Rueda CB; Rábano A; Satrústegui J; Ledesma MD
Mol Psychiatry; 2017 May; 22(5):711-723. PubMed ID: 27620840
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological reversion of sphingomyelin-induced dendritic spine anomalies in a Niemann Pick disease type A mouse model.
Arroyo AI; Camoletto PG; Morando L; Sassoe-Pognetto M; Giustetto M; Van Veldhoven PP; Schuchman EH; Ledesma MD
EMBO Mol Med; 2014 Mar; 6(3):398-413. PubMed ID: 24448491
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein D-mediated preservation of lysosomal function promotes cell survival and delays motor impairment in Niemann-Pick type A disease.
Pascua-Maestro R; Corraliza-Gomez M; Fadrique-Rojo C; Ledesma MD; Schuchman EH; Sanchez D; Ganfornina MD
Neurobiol Dis; 2020 Oct; 144():105046. PubMed ID: 32798728
[TBL] [Abstract][Full Text] [Related]
5. Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A.
Long Y; Xu M; Li R; Dai S; Beers J; Chen G; Soheilian F; Baxa U; Wang M; Marugan JJ; Muro S; Li Z; Brady R; Zheng W
Stem Cells Transl Med; 2016 Dec; 5(12):1644-1655. PubMed ID: 27484861
[TBL] [Abstract][Full Text] [Related]
6. Neutral sphingomyelinase increases and delocalizes in the absence of Toll-Like Receptor 4: A new insight for MPTP neurotoxicity.
Albi E; Cataldi S; Codini M; Mariucci G; Lazzarini A; Ceccarini MR; Ferri I; Laurenti ME; Arcuri C; Patria F; Beccari T; Conte C
Prostaglandins Other Lipid Mediat; 2019 Jun; 142():46-52. PubMed ID: 30928412
[TBL] [Abstract][Full Text] [Related]
7. Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency:the utility of animal models of disease in the toxicological evaluation of potential therapeutics.
Murray JM; Thompson AM; Vitsky A; Hawes M; Chuang WL; Pacheco J; Wilson S; McPherson JM; Thurberg BL; Karey KP; Andrews L
Mol Genet Metab; 2015 Feb; 114(2):217-25. PubMed ID: 25092414
[TBL] [Abstract][Full Text] [Related]
8. High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann Pick disease type A.
Gabandé-Rodríguez E; Boya P; Labrador V; Dotti CG; Ledesma MD
Cell Death Differ; 2014 Jun; 21(6):864-75. PubMed ID: 24488099
[TBL] [Abstract][Full Text] [Related]
9. Chronic visceral acid sphingomyelinase deficiency (Niemann-Pick disease type B) in 16 Polish patients: long-term follow-up.
Lipiński P; Kuchar L; Zakharova EY; Baydakova GV; Ługowska A; Tylki-Szymańska A
Orphanet J Rare Dis; 2019 Feb; 14(1):55. PubMed ID: 30795770
[TBL] [Abstract][Full Text] [Related]
10. Alterations of myelin-specific proteins and sphingolipids characterize the brains of acid sphingomyelinase-deficient mice, an animal model of Niemann-Pick disease type A.
Buccinnà B; Piccinini M; Prinetti A; Scandroglio F; Prioni S; Valsecchi M; Votta B; Grifoni S; Lupino E; Ramondetti C; Schuchman EH; Giordana MT; Sonnino S; Rinaudo MT
J Neurochem; 2009 Apr; 109(1):105-15. PubMed ID: 19187445
[TBL] [Abstract][Full Text] [Related]
11. Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease.
Dodge JC; Clarke J; Treleaven CM; Taksir TV; Griffiths DA; Yang W; Fidler JA; Passini MA; Karey KP; Schuchman EH; Cheng SH; Shihabuddin LS
Exp Neurol; 2009 Feb; 215(2):349-57. PubMed ID: 19059399
[TBL] [Abstract][Full Text] [Related]
12. Acid sphingomyelinase (aSMase) deficiency leads to abnormal microglia behavior and disturbed retinal function.
Dannhausen K; Karlstetter M; Caramoy A; Volz C; Jägle H; Liebisch G; Utermöhlen O; Langmann T
Biochem Biophys Res Commun; 2015 Aug; 464(2):434-40. PubMed ID: 26129774
[TBL] [Abstract][Full Text] [Related]
13. Degradation of fluorescent and radiolabelled sphingomyelins in intact cells by a non-lysosomal pathway.
Levade T; Vidal F; Vermeersch S; Andrieu N; Gatt S; Salvayre R
Biochim Biophys Acta; 1995 Oct; 1258(3):277-87. PubMed ID: 7548198
[TBL] [Abstract][Full Text] [Related]
14. Sphingomyelin 16:0 is a therapeutic target for neuronal death in acid sphingomyelinase deficiency.
Gaudioso Á; Jiang X; Casas J; Schuchman EH; Ledesma MD
Cell Death Dis; 2023 Apr; 14(4):248. PubMed ID: 37024473
[TBL] [Abstract][Full Text] [Related]
15. Enzyme activities and phospholipid storage patterns in brain and spleen samples from Niemann-Pick disease variants: a comparison of neuropathic and non-neuropathic forms.
Besley GT; Elleder M
J Inherit Metab Dis; 1986; 9(1):59-71. PubMed ID: 3014212
[TBL] [Abstract][Full Text] [Related]
16. Creation of a mouse model for non-neurological (type B) Niemann-Pick disease by stable, low level expression of lysosomal sphingomyelinase in the absence of secretory sphingomyelinase: relationship between brain intra-lysosomal enzyme activity and central nervous system function.
Marathe S; Miranda SR; Devlin C; Johns A; Kuriakose G; Williams KJ; Schuchman EH; Tabas I
Hum Mol Genet; 2000 Aug; 9(13):1967-76. PubMed ID: 10942425
[TBL] [Abstract][Full Text] [Related]
17. Permeability barrier disorder in Niemann-Pick disease: sphingomyelin-ceramide processing required for normal barrier homeostasis.
Schmuth M; Man MQ; Weber F; Gao W; Feingold KR; Fritsch P; Elias PM; Holleran WM
J Invest Dermatol; 2000 Sep; 115(3):459-66. PubMed ID: 10951284
[TBL] [Abstract][Full Text] [Related]
18. Studies on the activation of sphingomyelinase activity in Niemann-Pick type A, B, and C fibroblasts: enzymological differentiation of types A and B.
Poulos A; Ranieri E; Shankaran P; Callahan JW
Pediatr Res; 1984 Nov; 18(11):1088-93. PubMed ID: 6096798
[TBL] [Abstract][Full Text] [Related]
19. Role of sphingomyelinases in neurological disorders.
Ong WY; Herr DR; Farooqui T; Ling EA; Farooqui AA
Expert Opin Ther Targets; 2015; 19(12):1725-42. PubMed ID: 26243307
[TBL] [Abstract][Full Text] [Related]
20. Accurate differentiation of neuronopathic and nonneuronopathic forms of Niemann-Pick disease by evaluation of the effective residual lysosomal sphingomyelinase activity in intact cells.
Graber D; Salvayre R; Levade T
J Neurochem; 1994 Sep; 63(3):1060-8. PubMed ID: 8051547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
